Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
about
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
description
scientific article published on 14 February 2019
@en
name
Lomustine-temozolomide combina ...... sed, open-label, phase 3 trial
@en
type
label
Lomustine-temozolomide combina ...... sed, open-label, phase 3 trial
@en
prefLabel
Lomustine-temozolomide combina ...... sed, open-label, phase 3 trial
@en
P2093
P50
P1433
P1476
Lomustine-temozolomide combina ...... sed, open-label, phase 3 trial
@en
P2093
Astrid Weyerbrock
Bogdana Suchorska
Christina Schaub
Christoph Coch
Clemens Seidel
Dietmar Krex
Florian Ringel
Frederic Mack
Friederike Schmidt-Graf
Hartmut Vatter
P304
P356
10.1016/S0140-6736(18)31791-4
P577
2019-02-14T00:00:00Z